<u>Cancer Immune Monitoring and Analysis Centers</u> & <u>Cancer Immunologic Data Commons</u>

The CIMAC-CIDC Network



William D. Merritt, Ph.D.,

Program Director, Cancer Therapy Evaluation Program, DCTD, NCI



SITC Biomarkers Workshop May 16, 2018

CIMAC-CIDC Network OVERALL Goals and Structure

- CIMAC-CIDC Network is a pre-funded, standing laboratory and database resource to support correlative studies in early phase clinical trials involving immunotherapy
- Our goal: to help individual trials <u>maximize its translational potential</u> and to enhance the collective power of correlative studies across the NCI trial networks and funded programs
- Four (4) CIMACs and one CIDC are funded as U24 Cooperative Agreements
 - <u>CIMACs</u> provide assays and data analysis from biospecimens from NCIfunded immunotherapy trials
 - <u>CIDC</u> provides overall data integration platform to serve the network and eventually the larger IO research community

The CIMAC-CIDC Network

CIMACs

1. The University of Texas MD Anderson Cancer Center

PIs: Ignacio Wistuba and Chantale Bernatchez

2. Icahn School of Medicine at Mount Sinai PI: Sacha Gnjatic

3. Dana-Farber Cancer Institute PIs: Catherine Wu and F. Stephen Hodi

4. Stanford University

PIs: Holden Maecker and Sean Bendall

CIDC

Dana-Farber Cancer Institute

Pls: Xiaole Shirley Liu and Ethan Cerami

NCI Staff

Cancer Diagnostic Program:

- Magdalena Thurin (Program Director) **CTEP:**
 - Helen Chen
 - Elad Sharon
 - Howard Streicher
 - Bill Merritt (CITN)
 - Minkyung Song (Grant-supported trials)

CBIIT:

- David Patton
- BRP:
- Yingdong Zhao
- Laura Yee

TRP:

• Andrew Hruszkewycz (SPORE grants)

Jeff Abrams, DCTD Associate Director, CTEP

Administrative Support:

- Rebecca Enos
- Melissa Bowman

Scope of Work

- Each **CIMAC** is a <u>multidisciplinary</u> team (oncologists, pathologists, lab scientists, bioinformaticians, statisticians).
- In conjunction with CIDC, will provide assays AND analysis for immune biomarkers (including genomic, phenotypic and functional characterization) using state-of-the-art, consistent methodologies.
- All CIMACS will work as a network to collaborate on trials
 - Eligible trials Early (Phase 1 and Phase 2) immunotherapy trials
 - CTEP Trial Networks (NCTN, ETCTN, CITN, ABTC, PBTC)
 - NCI Grant-supported trials (eg. P01, R01, SPORE grants)
 - 600 patient-timepoint/year for comprehensive profiling
 - More patients if not all assays are feasible with available tissues
 - Can expand with supplemental funding (e.g. PACT or other resources)

Partnership for Accelerating Cancer Therapies (PACT)


Press release - October 12, 2017. <u>NIH partners with 11 leading</u> biopharmaceutical companies to accelerate the development of new cancer immunotherapy strategies for more patients



Foundation for the National Institutes of Health



CIMACs-CIDC Network Structure



- ALL CIMACs can work with <u>any</u> trial networks, depending on specific needs, expertise and work load
- Each CIMAC will be in a Primary Alignment with 1-2 trial Networks to facilitate scientific planning, Biobank interactions
- A given CIMAC may perform a specific assay for all trials

Oversight of CIMAC-CIDC Functions

Laboratory Coordinating Committee (LCC) Leader: Ignacio Wistuba Co-leaders: Catherine Wu, Holden Maecker, Sacha Gnjatic, Shirley Liu NCI Staff, Subject experts when appropriate					
Clinical Trials WG Network Leads: Stephen Hodi NCI Leader: Helen Chen	Biobank WG Network Leads: Ignacio Wistuba Ethan Cerami NCI Leaders: David Patton Irina Lubensky	Assays/Platforms WG Network Leads: Holden Maecker Catherine Wu Sacha Gnjatic NCI Leader: Magdalena Thurin	Database WG Network Leads: Ethan Cerami NCI Leader: David Patton	Bioinformatics/ Statistics WG Network Leads: Shirley Liu NCI Leader: Yingdong Zhao	Non-CTEP Network Trials WG NCI Leader: Min Song

Assays/Platforms in CIMACs

Tissue-based Imaging

- Multiplex immunohistochemistry
- Conventional immunohistochemistry
- FISH DNA
- Multiplexed Ion-Beam Imagining (MIBI)

Cell Profiling

- Mass Cytometry (CyTOF)
- High-dimensional flow cytometry
- ELISpot

Cytokines/Serum Analytes

- O-link serum cytokine analysis
- Luminex
- Seromics ELISA/Grand serology
- MesoScale Discovery

Sequencing

- Whole Exome Sequencing
- RNA-Seq
- NanoString
- TCR/BCR clonality
- Single-cell TCRseq
- HLA-Seq, Epitope prediction
- Cell-free DNA (circulating tumor DNA)
- HTG-EdgeSeq (gene expression)
- Single-cell transcriptome


Other:

- Neoantigen Prediction
- Mass spectrometry epitope detection
- Epigenomics (ATAC-Seq)
- Microbiome (16S Deep Sequencing)
- CRISPR
- Assays may be standardized and harmonized across Centers, or directed to a select center
- All assays must meet analytical characteristics that are fit for purpose

(Status as of March 2018)


- Blue text = Tier 1 assays
- Black text = Tier 2 assays

A. Overall Vision of CIDC



- Central Data Repository for CIMAC generated biomarker data, using standardized data format
 - Genomics, transcriptomics, proteomics, flow, IHC etc
- Secure Informatics Platform for integration of biomarker data and clinical data
- Role-based, time-controlled data access with web visualization by collaborating CIMAC and clinical team... and in the future, outside community
- Coordination of all network activities for biomarker discovery and validation

Work flow for CIMACs/CIDC Studies Linked to Network Clinical Trials




- 2. Database at CIDC including clinical data elements critical to correlative analysis
- **3.** Data analysis and Publication data analysis will be done collaboratively between the Trial Team and CIMAC

Current Status

- Pilot projects selected to demonstrate the function and optimize the process of CIMAC
- Harmonization/standardization for key platforms in progress
 ... in addition to assay validation documents
- Database and informatics pipeline being selected for key platforms
- Specimen tracking system across CIMACs and Biobanks and sites
- Various agreements under review (data access, data sharing, MTA, Institutional Certificates, specimen manifest...)

It Takes a Village!





www.cancer.gov/espanol

www.cancer.gov